Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Flat To Lower Premarket Wednesday

11/17/2021 | 09:14am EST


ę MT Newswires 2021
All news about VIR BIOTECHNOLOGY, INC.
01/14WHO recommendation on Merck's oral pill likely in early February
RE
01/13GSK-Vir, Eli Lilly's COVID-19 Treatments Recommended by WHO
MT
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/13GSK, Vir Biotechnology Seek US FDA's Nod to Amend Emergency Use Authorization for COVID..
MT
01/13Vir Biotechnology to Get Investment, Grant From Gates Foundation for HIV, Malaria Resea..
MT
01/13GlaxoSmithKline, Vir Biotechnology Apply to FDA to Amend EUA for COVID-19 Treatment
MT
01/13Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure ..
GL
01/13Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure ..
GL
01/13GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Adm..
AQ
01/13GlaxoSmithKline Secures $945.1 Million US Army Contract Modification
MT
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 696 M - -
Net income 2021 233 M - -
Net cash 2021 912 M - -
P/E ratio 2021 22,2x
Yield 2021 -
Capitalization 5 065 M 5 065 M -
EV / Sales 2021 5,97x
EV / Sales 2022 2,83x
Nbr of Employees 395
Free-Float -
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 38,70 $
Average target price 91,43 $
Spread / Average Target 136%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.-7.57%5 065
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684